Fexofenadine Hydrochloride Tablet, Film Coated
FDA Recall NDC 45802-847

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Fexofenadine Hydrochloride (NDC 45802-847). A significant event, classified as Class II, was initiated on Feb 09, 2023 by Padagis Israel Pharmaceuticals Ltd. The reported reason for this action was: "Failed Impurities/Degradation Specifications"

This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.

Reported Recall Events

February 2023 Class II Recall: Failed Impurities/Degradation Specifications

Recall Number
Class II Terminated
Reason for Recall
Failed Impurities/Degradation Specifications
Initiated
Feb 09, 2023
Reported
Jul 19, 2023
Quantity
15,504 cartons

Recall Profile & Regulatory Data

Event ID
91672
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
L. Perrigo Company
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide within the USA
Termination Date
Sep 11, 2023
Product Description
Fexofenadine Hydrochloride Tablets, 180 mg, 100-count cartons, Distributed by: Perrigo, Allegan, MI 49010. NDC 45802-847-78
Batch or Lot Expiration Information
Lot# : 2DR0351, Exp. date 12/23
Affected Packages Involved in this Recall
45802-847-78Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.